GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The new incretin-based therapies offer appealing advantages over existing drugs. Aside from
glucose dependent insulin secretion and a proven glucose lowering efficacy, they have other
concomitant beneficial effects, such as low risk of hypoglycemia, inhibition of the glucagon
secretion with maintenance of counter-regulatory mechanism, promotion of weight loss, and
possible cardiovascular benefits (improvement of lipid profile, blood pressure, endothelial
and myocardial function). The glucose lowering effects resulting from the inhibition of
glucagon secretion and the gastric emptying rate could be of clinical importance in type 1
diabetes.
The rationale behind the use of GLP-1 analogues in the treatment of type 1 diabetes relies on
the assumption that these drugs, in addition to their action on insulin secretion and glucose
regulation, may be effective in preserving and even expanding the β-cell mass. This class of
drugs may represent an entirely new approach to the treatment of type 1 diabetes, focused on
protection and preservation of β-cells. These therapies have the opportunity to interfere
with the disease progression if used as an early intervention, when enough β-cell mass/
function can still be preserved or restored.
Hypothesis:
GLP-1 analogue (liraglutide) will improve glycemic control as measured by HbA1c in
uncontrolled type 1 diabetic patients. The investigators expect a reduction of 1% in HbA1C
from baseline.